-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on April 28.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
The National Health Commission held a press conference on the 27th.
A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
He Jie said that the Party Central Committee and the State Council attach great importance to the protection of anti-cancer drugs, especially since the 19th National Congress of the Communist Party of China, the price of anti-cancer drugs has been drastically reduced through national medical insurance negotiations and other means to increase the availability of anti-cancer drugs.
National Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
National Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
According to Hejie, starting in 2018, under the direct leadership of the National Health Commission, the National Cancer Center has established an anti-cancer drug clinical application monitoring network.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
"In addition, by monitoring the reasonable diagnosis and treatment behavior of tumors and the rational use of anti-tumor drugs, the entire medical behavior specification is strengthened.
For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
He also pointed out that the Czech Republic, at different levels, hospitals, different classes of anti- tumor drugs configuration and usage levels of the drug or different, not the same as the level of the hospital, the doctor's level is not the same, certainly there will be some differences.
"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
Hejie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, and better guide the clinical rational deployment and use of anti-tumor drugs, and contribute to the national health.
The Health Commission provides a reference basis for the assessment of various medical institutions.
The Health Commission provides a reference basis for the assessment of various medical institutions.
Medical Network News on April 28.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
The National Health Commission held a press conference on the 27th.
A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
He Jie said that the Party Central Committee and the State Council attach great importance to the protection of anti-cancer drugs, especially since the 19th National Congress of the Communist Party of China, the price of anti-cancer drugs has been drastically reduced through national medical insurance negotiations and other means to increase the availability of anti-cancer drugs.
National Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
National Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
According to Hejie, starting in 2018, under the direct leadership of the National Health Commission, the National Cancer Center has established an anti-cancer drug clinical application monitoring network.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
"In addition, by monitoring the reasonable diagnosis and treatment behavior of tumors and the rational use of anti-tumor drugs, the entire medical behavior specification is strengthened.
For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
He also pointed out that the Czech Republic, at different levels, hospitals, different classes of anti- tumor drugs configuration and usage levels of the drug or different, not the same as the level of the hospital, the doctor's level is not the same, certainly there will be some differences.
"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
Hejie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, and better guide the clinical rational deployment and use of anti-tumor drugs, and contribute to the national health.
The Health Commission provides a reference basis for the assessment of various medical institutions.
The Health Commission provides a reference basis for the assessment of various medical institutions.
Medical Network News on April 28.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
Can anti-tumor drugs enter the hospital after entering the medical insurance? What is the current clinical use of these drugs? On the 27th, He Jie, academician of the Chinese Academy of Sciences and director of the National Cancer Center, responded.
The data shows that the average number of anti-tumor drugs in hospitals monitored by the surveillance network in 2020 has increased by 15% over the previous year, and the average number of inpatients using these drugs An increase of 6%, while the average cost has dropped by 8%, and the average cost of some more expensive immunotherapy drugs and targeted therapy drugs has decreased by 50%-70%.
The National Health Commission held a press conference on the 27th.
A reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
Hospital hospital hospitalA reporter asked: At present, many anti-tumor drugs, especially new drugs, have been launched one after another.
The state has also conducted some medical insurance negotiations.
The people are more concerned about whether anti-tumor drugs can enter medical insurance.
Into the hospital ? What is the current clinical use of these drugs?
He Jie said that the Party Central Committee and the State Council attach great importance to the protection of anti-cancer drugs, especially since the 19th National Congress of the Communist Party of China, the price of anti-cancer drugs has been drastically reduced through national medical insurance negotiations and other means to increase the availability of anti-cancer drugs.
National Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
Healthy, healthy, healthyNational Health Health Commission attaches great importance to this work, one is requiring all medical institutions in a timely manner to configure these drugs, on the other hand requires various medical institutions rational use of anticancer drugs.
According to Hejie, starting in 2018, under the direct leadership of the National Health Commission, the National Cancer Center has established an anti-cancer drug clinical application monitoring network.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
This is the monitoring of anti-cancer drugs in more than 1,400 large hospitals across the country.
The monitoring has promoted anti-cancer drugs.
Standard and rational use of tumor drugs.
The data shows that in 2020, the average number of anti-tumor drugs in hospitals monitored by the Surveillance Network has increased by 15% over the previous year.
The average number of inpatients using these drugs has increased by 6%, while the average cost has dropped by 8%.
, The cost of some more expensive immunotherapy drugs and targeted therapy drugs has dropped by 50%-70% per time.
This shows that the availability of anti-tumor drugs has been significantly improved.
"In addition, by monitoring the reasonable diagnosis and treatment behavior of tumors and the rational use of anti-tumor drugs, the entire medical behavior specification is strengthened.
For example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
Standard Standard StandardFor example, in 2020, we conducted statistics on the monitored hospitals and found that the pathological examination of patients using anti-tumor drugs The gold standard has increased by 6% compared with the previous year, which means it is more standardized.
" Hejie added.
He also pointed out that the Czech Republic, at different levels, hospitals, different classes of anti- tumor drugs configuration and usage levels of the drug or different, not the same as the level of the hospital, the doctor's level is not the same, certainly there will be some differences.
"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
Tumor tumor tumor"We are gradually improving through homogeneity, just like the quality control just mentioned, and gradually make up for the weaknesses in this area.
"
Hejie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, and better guide the clinical rational deployment and use of anti-tumor drugs, and contribute to the national health.
The Health Commission provides a reference basis for the assessment of various medical institutions.
The Health Commission provides a reference basis for the assessment of various medical institutions.
